ArticleIn vivo (Athens, Greece)
Clinical Impact of Preoperative Albumin-Bilirubin Status in Esophageal Cancer Patients Who Receive Curative Treatment.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Albumin-Bilirubin Score as a Novel Prognostic Prediction Tool for Surgically Treated Head and Neck Squamous Cell Carcinoma.The Kaohsiung journal of medical sciences · 2026Article
- Serum Bilirubin as a Prognostic Factor in Lung Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Genetic evidence for causal relationships between vegetarian biomarkers and esophageal cancer risk.Discover oncology · 2025Article
- Albumin-bilirubin score: a promising predictor of postoperative distant metastasis in patients with colorectal cancer.Biomarkers in medicine · 2025Article
- Bilirubin metabolism in relation to cancer.Frontiers in oncology · 2025Review
- Predictive Value of GINI and ALBI Grades in Esophageal Cancer Receiving Chemoradiotherapy.Current oncology (Toronto, Ont.) · 2024Article
- Gut Microbiota, Human Blood Metabolites, and Esophageal Cancer: A Mendelian Randomization Study.Genes · 2024Article
- Phosphate-to-alanine ratio and bilirubin-to-androsterone glucuronide ratio are the hub metabolites in upper gastrointestinal cancers: a Mendelian randomisation (MR) study.Ecancermedicalscience · 2024Review
- Association of easy albumin-bilirubin score with increased mortality in adult trauma patients.Frontiers in surgery · 2024Article
- Evaluation of the Easy Albumin-Bilirubin Score as a Prognostic Tool for Mortality in Adult Trauma Patients in the Intensive Care Unit: A Retrospective Study.Diagnostics (Basel, Switzerland) · 2023Article
- Novel prognostic score based on the preoperative total bilirubin-albumin ratio and fibrinogen-albumin ratio in ampullary adenocarcinoma.World journal of gastrointestinal surgery · 2023Article
- Preoperative albumin-bilirubin score is a prognostic factor for gastric cancer patients after curative gastrectomy.World journal of gastrointestinal surgery · 2023Article
- The Association of Albumin-Bilirubin (ALBI) Grade with Mortality Risk in Trauma Patients with Liver Injuries.Risk management and healthcare policy · 2023Article
- Analysis of the albumin-bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct-acting antiviral therapy.JGH open : an open access journal of gastroenterology and hepatology · 2022Article
- Skeletal Muscle Loss During Neoadjuvant Chemotherapy Predicts the Incidence of Postoperative Infectious Complications in Esophageal Cancer Patients Undergoing Esophagectomy.Cancer diagnosis & prognosisArticle
- Inflammatory Burden Index Is an Independent Prognostic Factor for Esophageal Cancer Patients Who Receive Curative Treatment.In vivo (Athens, Greece)Article
- Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer.In vivo (Athens, Greece)Article
- Association of Pretreatment Albumin-bilirubin Grade With Hepatotoxicity and Efficacy in EGFR-TKIs Therapy for NSCLC.Cancer diagnosis & prognosisArticle
- Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThe albumin-bilirubin (ALBI) score, which evaluates the perioperative liver function, was developed, and had a clinical impact on both the short- and long-term oncological outcomes in some malignancies. We evaluated the clinical impact of preoperative albumin-bilirubin status in patients with resectable esophageal cancer who received curative treatment. PATIENTS AND
methodsThe study included 121 patients who underwent curative surgery followed by adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified.
resultsBased on the 3- and 5-year OS rates, we set the cut-off value for the ALBI score at -2.7. Eighty patients were classified into the ALBI-low group (ALBI score <-2.7), 41 patients were categorized into the ALBI-high group (ALBI score >-2.7). The 3- and 5-year OS rates were 62.2% and 53.2%, respectively, in the ALBI-low group, and 42.2% and 35.2% in the ALBI-high group. There was a significant difference in OS (p=0.0113). The 3- and 5-year RFS rates were 43.1% and 40.3%, respectively, in the ALBI-low group and 37.7% and 26.1% in the ALBI-high group. There was a significant difference in RFS (p=0.048). When comparing the perioperative clinical course between the ALBI-high and ALBI-low groups, the incidence of postoperative anastomotic leakage was 46.3% (19/41) in the ALBI-high group, and 27.5% (22/80) in the ALBI-low group (p=0.038).
conclusionThe ALBI status had a clinical impact on both OS and RFS in esophageal cancer patients. Therefore, ALBI may have potential application as a prognostic factor for esophageal cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.